Mumbai, Maharashtra, India
Diabetes is a growing epidemic in the United States, with the number of people diagnosed with the disease increasing more than two-fold over the past 15 years. As current treatments leave room for improvement within an area of unmet medical need, a myriad of companies are working on new types of drug products to better control and prevent diabetes and its subsequent complications.
New analysis from Frost & Sullivan (http://www.pharmaceuticals.frost.com), U.S. Diabetes Pipeline Outlook, reveals that more than 70 drugs are currently in clinical development for diabetes. Additionally, it provides discussion and analysis on the leading areas in the diabetes pipeline, including class dynamics and competitive factors for new product types.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Diabetes Pipeline Outlook, then send an e-mail to Shwetha Thomas - Corporate Communications at sthomas@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
"New pipeline technologies have the potential to positively change diabetes therapy," says Frost & Sullivan Industry Manager Daniel Ruppar. "They also have the ability to create new treatment options and pathways for patients and physicians."
Diabetes is currently an area of unmet medical need. Multiple new product types with the potential to improve diabetes therapy are currently in clinical development. Additionally, new technology products, such as Byetta, Januvia, and Exubera, are leading the way as first-in-class drugs that could make a positive impact in the near term.
Pharmaceutical companies are constantly seeking new drugs that can improve the treatment of diabetes and create new sources for revenue growth. In order to be successful, new products must differentiate themselves from current therapies. Furthermore, they must demonstrate advantages in characteristics such as efficacy and safety. In order for the healthcare community and payers to embrace new product technologies, the therapeutic ROI must be well outlined and demonstrated.
"New diabetes products are of high interest to physicians and patients," explains Ruppar. "However, the industry must effectively demonstrate the benefits of these new technologies over current treatments in order for them to find their niche."
To judge how a novel product might fare in the marketplace, it is essential that they demonstrate how they can work with, improve upon, or replace current products. Diabetes drugs that are in the pipeline today could improve treatment outcomes and greatly help patients in the future fight the disease.
The U.S. Diabetes Pipeline Outlook is part of the Pharmaceutical & Biotechnology Growth Partnership Service, and provides insight and discussion of the drugs in clinical development for diabetes treatment in the United States. In this study, Frost & Sullivan's expert analysts thoroughly examine the following technologies: GLP-1 Agonists, DPP-IV inhibitors, pulmonary insulin, PPAR modulators, and other pipeline efforts. Interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
U.S. Diabetes Pipeline Outlook
N097
Source: Frost & Sullivan (Business Wire India)